Optimind Pharma Corp. (CSE:OMND)

Optimind Pharma Income Statement

Financials in millions CAD. Fiscal year is March - February.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Nov 30, 2024	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022
Revenue	0.11	0.12	0.17	0.1
Revenue Growth (YoY)	-19.31%	-27.72%	70.64%	-
Cost of Revenue	0.04	0.06	0.12	0.04
Gross Profit	0.07	0.06	0.05	0.06
Selling, General & Admin	0.39	0.51	0.92	0.44
Research & Development	-	0.12	-	-
Operating Expenses	0.39	0.81	0.96	0.47
Operating Income	-0.32	-0.75	-0.91	-0.4
Interest Expense	-0.01	-0.09	-0.07	-0.02
Other Non Operating Income (Expenses)	-0.21	-0.21	-0.03	-
EBT Excluding Unusual Items	-0.53	-1.05	-1.01	-0.42
Impairment of Goodwill	-	-	-0.86	-
Gain (Loss) on Sale of Investments	-	-	-0.31	-
Asset Writedown	-0.37	-0.37	-0.65	-
Other Unusual Items	-	0.02	-0.26	-
Pretax Income	-0.9	-1.41	-3.09	-0.42
Income Tax Expense	-0.01	-0.01	-0.01	-0.14
Net Income	-0.9	-1.4	-3.08	-0.28
Net Income to Common	-0.9	-1.4	-3.08	-0.28
Shares Outstanding (Basic)	110	100	82	44
Shares Outstanding (Diluted)	110	100	82	44
Shares Change (YoY)	12.33%	21.38%	88.09%	-
EPS (Basic)	-0.01	-0.01	-0.04	-0.01
EPS (Diluted)	-0.01	-0.01	-0.04	-0.01
Gross Margin	65.23%	47.63%	30.49%	63.89%
Operating Margin	-283.02%	-612.59%	-533.41%	-405.39%
Profit Margin	-804.03%	-1136.63%	-1809.57%	-278.57%
EBITDA	-	-0.74	-0.89	-0.39
D&A For EBITDA	-	0.01	0.01	0.01
EBIT	-0.32	-0.75	-0.91	-0.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.